Leveraging its inherent biocompatibility and demonstrated hemostatic capabilities, chitosan has emerged as a cornerstone biomaterial in advanced wound management systems, particularly for exuding and traumatic injuries. However, the poor mechanical strength of the formed clots can lead to a high risk of secondary bleeding. Here, this study has successfully developed chitosan hemostatic particles (M-CS) capable of arresting arterial hemorrhage by particle size distribution and combining this with lauric acid modification. By integrating physical obstruction, electrostatic forces, and hydrophobic effects, M-CS creates a dense clot matrix that withstands arterial blood flow independently of systemic coagulation pathways. In vitro coagulation tests showed that M-CS reduced whole blood clotting time by 23% compared to unmodified CS. Based on rheological characterization, the M-CS-formed clot matrix demonstrated a 48% higher storage modulus than the commercially available CELOX^TM and a five-fold increase over the control group. Moreover, in a Bama minipig femoral artery injury model, M-CS achieved successful hemostasis within 300 s, and reduced blood loss by 12%. The findings lay a robust technological groundwork not only for enhanced hemostatic stability in arterial bleeding management but also for expedited translational advancement in pre-hospital emergency care, particularly for compressible truncal hemorrhage.

Hemostatic Material, Chitosan, Arterial Hemorrhage, Emergency Medical Response